TITLE:
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa

CONDITION:
Epidermolysis Bullosa

INTERVENTION:
isotretinoin

SUMMARY:

      OBJECTIVES:

      I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis
      bullosa.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE:

      Patients receive oral isotretinoin daily for 8 months in the absence of disease progression
      or unacceptable toxicity.

      Completion date provided represents the completion date of the grant per OOPD records
    

ELIGIBILITY:
Gender: All
Age: 15 Years to N/A
Criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) RDEB Hallopeau-Siemens
             OR RDEB non-Hallopeau-Siemens

          -  Concurrent enrollment in the National Epidermolysis Bullosa Registry

          -  No regional or distant metastasis in patients with previous or concurrent squamous
             cell carcinoma

        --Patient Characteristics--

          -  Hepatic: No clinically significant hypertriglyceridemia No clinically significant
             hepatic dysfunction

          -  Renal: No clinically significant renal dysfunction

          -  Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use
             effective contraception
      
